novo nordisk semaglutide direct faces 'must-win' battle over U.S. Wegovy, Ozempic in 2026 Novo Nordisk asks FDA to

In recent years, GLP-1 medications have taken the health and wellness world by storm, offering hope to millions struggling with weight loss and metabolic health

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.

Hartford, CT

The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said

Our GLP-1 weight loss marketing campaign templates are created with the same level of strategy and meticulous design as if you were working with us one on one

Everything is going up, so I locked one thing down